BST1 and acute myeloid leukemia: MEN1112/OBT357, a defucosylated, humanized, CD157-specific, monoclonal IgG1 has been generated and designed by Oxford BioTherapeutics (Oxford, UK) with the aim of overcoming the NK impairment in AML.